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Abstract A recombinant version of the receptor binding domain 
of rat at-macroglobulin (RBDv) consisting of residues 1319-1474 
has been expressed in E. coil. Competition experiments with 
USl-labelled methylamine treated human a2-macroglobulin reveal 
that the th-macroglobulin-RBDv exhibit the same high affinity 
for the c~2-macroglobulin receptor as the entire 40 kDa light chain 
from rat a~-macroglobulin. It is therefore concluded, that all 
determinants for receptor interaction reside in the C-terminal 
approx. 150 residues of the t~-macroglobulin subunit. 
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I. Introduction 
Rat ~-macroglobulin (oqM) belongs to the ~-macroglob- 
ulins (czMs), most of which are large tetrameric proteinase 
inhibitors present in the blood of vertebrates and invertebrates 
and in bird and reptile egg-white. Upon interaction of pro- 
teinases with ~Ms a large structural rearrangement, known as 
transformation is initiated by cleavage within the exposed 'bait 
regions', resulting in entrapment and inhibition of the pro- 
teinase (for reviews, see [1,2]). Transformation of c~Ms exposes 
a previously concealed receptor binding domain, important for 
the rapid clearance from the circulation [3-5]. The receptor for 
transformed czMs termed ~zMR/LRP [6-8] consists of a 515 
kDa ligand binding s-chain and a 85 kDa membrane spanning 
fl-chain [9-11]. ~2MR/LRP is present in many tissues, including 
fibroblasts, adipocytes, macrophages and hepatocytes 
[3,5,12,13]. In addition to ~M-proteinase complexes the recep- 
tor binds ligands of several classes, such as plasminogen activa- 
tor inhibitor-plasminogen activator complexes, lipoprotein li- 
pases and c~2-macroglobulin receptor associated protein (~2M- 
RAP) [6,10,11,14-18]. 
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macroglobulin receptor/low density lipoprotein receptor-related pro- 
tein; ~z2M-RAP, ~2-macroglobulin receptor associated protein; =IM- 
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The receptor binding domain of ~Ms reside in their C-termi- 
nal region, and from several ~Ms an approx. 138-residue C- 
terminal fragment can be released by limited proteolysis (RBD) 
[19-21]. The affinity of the ~2M-RBD fragment for ~2MR/LRP 
is approx. 100 nm, i.e. only 0.14).2% of that of intact ~2M- 
proteinase complexes [19-21]. 
The subunit of rat CZlM is processed to a 1200 residue N- 
terminal heavy chain and a 250 residue C-terminal light chain 
[22], and since the ~lM light chain seems to bind to ~2MR/LRP 
with higher affinity than RBD [21] it has been questioned 
whether RBD contains complete information for receptor bind- 
ing [21]. 
In a previous paper [23] we showed that a human ~2M-RBD 
variant binding ~2MR/LRP with high affinity (8 nM) could be 
produced by including 15 upstream residues from the cc2M 
sequence (~2M-RBDv). The K a of the c~2M-RBDv is of the same 
order of magnitude as for the interaction of one monomer of 
intact activated c~2M with ~2MR/LRP [10]. In the present study 
we extend this result by demonstrating that a corresponding 
construct based on the rat C~lM sequence produces a rat ~M-  
RBD variant which has significantly higher affinity for ~2MR/ 
LRP than a rat 0qM construct corresponding to human ~zM- 
RBD [24]. This result shows that the proper structural domain 
boundary of both ~M-RBDs is located within the upstream 
15-residue segment. 
2. Materials and methods 
2.1. Synthesis of glutathione-Sepharose 
Glutathione-Sepharose (GSH-Sepharose) was synthesised from 25 g 
of drained Sepharose CL-6B, activated with 1,1'-carbonyldiimidazole 
[25]. 2.5 g of reduced glutathione was dissolved in 0.1 M Na-phosphate 
(pH 7.0) and oxidised on ice with 0.9 ml of 30% hydrogen peroxide. 
Oxidised glutathione was added to the gel suspension and mixed over- 
night. After blocking of remaining roups with 1 M ethanolamine for 
4 h and extensively washing of the gel with 0.1 M Na-phosphate (pH 
7.0), the gel was washed with degassed water and treated with 20 mM 
dithiothreitol. The reduced immobilised glutathione was then treated 
with 20 mM 5,5'-dithiobis(2-nitrobenzoic ac d) (DTNB). After exten- 
sive washing of the matrix with water it was packed into a column and 
kept refrigerated in the dark until use. 
2.2. Fusion protein design and E. coli expression vector construction 
To allow for initial affinity purification of fusion protein, immobilisa- 
tion of fusion protein to glutathione-Sepharose by disulfide links and 
final liberation of ~IM-RBDv by factor Xa cleavage, we devised a four 
segment fusion protein by joining sequences ncoding a hexahistidine 
tag, a GSCTGS hexapeptide, a factor X, recognition sequence and the 
~M-RBDv cDNA fragment. Vector assembly strategy and methods 
paralleled those given in [23], except hat the linker inserted at the 
vectors BamHI site was designed to encode the GSCTGS peptide seg- 
ment. The construction was verified by DNA sequencing using SE- 
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2.3. Purification, refolding and processing of ot~M-RBDv fusion protein 
Following solvation of the crude protein pellet in guanidinium chlo- 
ride and buffer exchange into 50 mM Tris-HC1, 8 M urea, 0.5 M NaC1, 
11~ mM 2-mercaptoethanol (pH8.0), by gel filtration on Sephadex G-25 
the protein extract was applied to a 40 ml Ni~+-NTA-Sepharose column 
[26]. After washing the column with 50 mM Tris-HC1, 6 M guanidinium 
chloride, 10 raM 2-mercaptoethanol (pH8.0), the column was washed 
~ith 50 mM Tris-HC1, 8 M urea, 0.5 M NaC1 and the bound protein 
~as eluted with 50 mM Tris-HC1, 8 M urea, 0.5 M NaCI, 10 mM EDTA 
(pH 8.0). This pool was applied to a glutathione-Sepharose c lumn and 
rcfolded while immobilised on the column using an iterative refolding 
p, ocedure. The fusion protein exhibited a tendency to aggregate, so in 
o~ der to achieve maximum yield of a~ M-RBDv, the cleavage with FX, 
u liberate the domain from the fusion tail was performed while immo- 
b~ [ised on the GSH-sepharose, by applying 1 mg of FX, dissolved in 
2 ml of 50 mM Tris-HCl, 0.5 M NaCl, 2 mM CaCI2 (pH 8) to the 
o 4umn and circulating this pool for 16 h. Gel filtration into a buffer 
o low ionic strength and ion-exchange chromatography onQ-Sepha- 
r,,se (Pharmacia) yielded pure ~M-RBDv. The concentration f the 
M-RBDv was determined by amino acid analysis. 
2 4. Preparation of~zM-LC 
Rat cqM was first treated with 0.2 M methylamine to cleave its 
iv ternal thiolesters, and then fully reduced with dithiothreitol followed 
b ~ treatment with iodoacetamide to block all SH-groups. Heavy and 
light chains of carboxamidomethylated ~,M were separated by gel 
titration on a Superose 12 column equilibrated and eluted with 50 mM 
"1 :is-HCl, 6 M guanidinium chloride (pH 8.0) essentially according to 
[?1]. The denaturant was removed by dialysis against 50 mM Tris-HC1 
(I,H 8.0). 
2 5. Amino acid composition analys& 
After hydrolysis for 20 h at 110°C in vacuo in 6 M HC1, 0.1% phenol, 
5 ~ thioglycollic acid the amino acid composition was determined by 
c ttion-exchange chromatography [27] modified as in [28]. 
2 6. Determination of aJfinity of binding to the a2MR/LRP 
Competition assays using 10 pM [~z~I]a2M-MA as competitor were 
p~rformed as in [23]. 100% binding was 401%600 cpm above a back- 
~'z'ound of 5-10 cprn. Non-specific binding to wells not coated with 
~MR/LRP was less than 0.5% of binding of the added tracer. 
3. Results 
Expression in E. coil and protein purification, refolding and 
I rocessing were monitored by SDS-PAGE and the final prepa- 
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Fig. 2. Alignment of the N-terminal border of the receptor binding 
domains of 8 macroglobulins. Asterisks indicate the presence of 6 or 
more identically ocated residues. The beginning ofauthentic RBD and 
recombinant RBDv is indicated. The numbering ofhuman c~2M is used. 
ration produced one band consistent with a molecular mass of 
approx. 17 kDa, in agreement with the expected mass of 17783 
Da. 
The amino acid composition of cqM-RBDv was in excellent 
agreement with that expected. By gel filtration on a Superose 
12 column under non-denaturing condition ~M-RBDv eluted 
as a monomeric protein of approx. 18 kDa even after several 
rounds of freezing and thawing. In contrast, cqM-LC eluted in 
the void volume of the column under the same conditions, 
showing that the product, although soluble, was extensively 
aggregated [30]. 
Fig. 1 shows the concentration dependence of inhibition of 
binding of I0 pM [~25I]~2M-MA to immobilised 0~2MR/LRP by 
unlabelled ~,M-RBDv and ~M-LC.  Half-maximal binding is 
observed at 12 and 8 nM, respectively. In contrast, the prote- 
olytic RBD fragment isolated from ~2M-MA produces half- 
maximal binding at approximately 100 nM [19-21]. The affinity 
o f~M-MA is higher, consistent with the suggestion that tetra- 
meric cqM-MA is able to bind to adjacent receptor molecules 
[10]. 
4. Discuss ion 
The molecular events resulting in binding, endocytosis and 
degradation of the ~M-proteinase complex to the ~2MR/LRP 
are not well understood. We have developed a system in which 
we are able to refold a variant of the receptor binding domain, 
(residues 1299 1451; RBDv) from human ~2M and have shown 
that the affinity of this fragment is approx. 10 times higher than 
the affinity of the proteolytically derived RBD-fragment (resi- 
dues 1314-1451). 
Expression in E. coil of a fragment from cqM (MetGlu m4- 
Ala ~4v7) with receptor binding properties was recently reported 
[22]. This fragment corresponds to human ~2M-RBD and the 
apparent Kd for the interaction with ~2MR/LRP was reported 
to 20 nM. The determination f K~ was, however, based on an 
I%, l cm E 28o of 11.5. In contrast, we find that our longer fragment has 
l% , l cm anE 28o of 6.0.Thecalculatedvalue[31] 1~ l~m" ofE 280 is 5.2 for resi- 
dues 1322 1477 (RBD), so the actual dissociation constant is 
likely to be higher than 40 nM, approaching that determined for 
human a~M-RBD [19-21]. The ~jM-RBDv expressed in this 
stu E~, km dy ( ~'80 determined tobe 6.0) appears to be correctly folded 
since it, once purified and liberated from the fusion protein 
construct, appears monomeric in gel filtration under non-dena- 
turing conditions. 
K d for in vitro binding of ~jM-RBDv to c~2MR/LRP was 
determined to be 12 nM, similar to the value estimated for the 
binding of ~,M-LC to c~2MR/LRP. Hence recombinant ~,M- 
RBDv represents a domain with considerably higher affinity 
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for the receptor than recombinant Met -~M-RBD and our data 
do not support he previous uggestion [21] that the approx. 100 
residues upstream of RBD in the ~l M light chain contain addi- 
tional determinants for receptor binding. 
An alignment of the sequences of the N-terminal border of 
the receptor binding domains is shown in Fig. 2. It is evident 
that the additional 15-residue segment included in our RBDv 
construct is part of a highly conserved segment comprising 
residues 1292-1314. A variant comprising residues 1292-1451 
of human ~2 M, where Cys j298 was replaced with a serine has 
also been expressed and refolded but no additional increase in 
affinity was obtained (data not shown). 
We have therefore now located the proper domain boundary 
for both aMs to the region 1299-1313 (human 0~2M numbering) 
by generating authentic recombinant fragments accounting for 
the receptor binding affinity in quantitative t rms. 
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